| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/06/2001 | US6183734 Inhibition of tumor cell growth by administration of B7-transfected cells |
| 02/06/2001 | CA2314849A1 Topical composition comprising a tocopherol compound |
| 02/06/2001 | CA2147807C Bicyclic-aromatic compounds; pharmaceutical and cosmetic compositions containing them and uses |
| 02/06/2001 | CA2141572C Terfenadine metabolites and their optically pure isomers for treating allergic disorders |
| 02/06/2001 | CA2003538C Collagen-polymer conjugates |
| 02/03/2001 | CA2314746A1 Use of flupirtin for amelioration of pains in the degenerative joint diseases of dogs and cats |
| 02/01/2001 | WO2001007918A1 Catalytic anti-factor viii allo-antibodies |
| 02/01/2001 | WO2001007914A1 Fenretinide increases antibody cellular toxicity |
| 02/01/2001 | WO2001007651A2 Transposon mediated differential hybridisation |
| 02/01/2001 | WO2001007628A2 Human synthetases |
| 02/01/2001 | WO2001007612A2 Receptors and associated proteins |
| 02/01/2001 | WO2001007611A2 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | WO2001007595A2 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | WO2001007480A2 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 02/01/2001 | WO2001007475A1 Novel peptides |
| 02/01/2001 | WO2001007471A2 Cell cycle and proliferation proteins |
| 02/01/2001 | WO2001007470A2 Human nervous system-associated proteins |
| 02/01/2001 | WO2001007469A2 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | WO2001007459A1 29 human secreted proteins |
| 02/01/2001 | WO2001007442A1 Beta-amyloid peptide inhibitors |
| 02/01/2001 | WO2001007088A2 Methods for treating therapy-resistant tumors |
| 02/01/2001 | WO2001007087A2 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | WO2001007082A1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| 02/01/2001 | WO2001007074A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | WO2001007072A1 Modulation of platelet activation |
| 02/01/2001 | WO2001007069A1 In vivo induction for enhanced function of isolated hepatocytes |
| 02/01/2001 | WO2001007067A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | WO2001007066A2 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | WO2001007056A1 Method of promoting bone growth with hyaluronic acid and growth factors |
| 02/01/2001 | WO2001007054A1 Methods for treating autoimmune diseases |
| 02/01/2001 | WO2001007050A1 Nociceptin receptor orl-1 agonists for use in treating cough |
| 02/01/2001 | WO2001007034A1 Multidrug resistance pump inhibitors and uses thereof |
| 02/01/2001 | WO2001007030A2 Compositions an inhibitor of an accrab-like efflux pump for reducung microbial resistance to drugs |
| 02/01/2001 | WO2001007027A2 Pyrimidine derivatives for the treatment of viral diseases |
| 02/01/2001 | WO2001007021A2 Process for the improvement of spermatozoa fertilization activity |
| 02/01/2001 | WO2001006990A2 Use of etodolac to treat cancer |
| 02/01/2001 | WO2001006987A2 Transnasal anticonvulsive compositions and modulated process |
| 02/01/2001 | WO2000067735A3 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION |
| 02/01/2001 | WO2000066722B1 Collection of prokaryotic dna for two hybrid systems helicobacter pylori protein-protein interactions and application thereof |
| 02/01/2001 | WO2000063352A3 Human homologues of fused gene |
| 02/01/2001 | WO2000059493A3 Improved dialysis solutions and methods |
| 02/01/2001 | WO2000056362A3 Polycationic carbohydrates as immunostimulants in vaccines |
| 02/01/2001 | WO2000054764A3 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 02/01/2001 | WO2000053742A3 Polynucleotides and proteins encoded thereby |
| 02/01/2001 | WO2000051583A3 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists |
| 02/01/2001 | WO2000050022A3 Treatment regimen for hormone-sensitive cancers |
| 02/01/2001 | WO2000049043A3 Human lipid-associated proteins |
| 02/01/2001 | WO2000043781A3 Growth differentiation factor inhibitors and uses therefor |
| 02/01/2001 | WO2000042832A3 New compounds for the treatment of cancer |
| 02/01/2001 | WO2000040226A3 Method of treating sexual disturbances |
| 02/01/2001 | WO2000038717A3 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia |
| 02/01/2001 | WO2000037107A3 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |
| 02/01/2001 | WO2000003743A3 Use of inhibitors of prenyltransferases for inhibiting fungal growth |
| 02/01/2001 | WO1999066951A8 Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 02/01/2001 | WO1997045137A8 Methods and compositions useful for inhibition of angiogenesis |
| 02/01/2001 | CA2718926A1 Methods of reducing microbial resistance to drugs |
| 02/01/2001 | CA2696819A1 Ghrelin related peptides |
| 02/01/2001 | CA2689694A1 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | CA2383690A1 29 human secreted proteins |
| 02/01/2001 | CA2380317A1 Human synthetases |
| 02/01/2001 | CA2380226A1 Novel fibroblast growth factor and nucleic acids encoding same |
| 02/01/2001 | CA2380178A1 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | CA2380171A1 Transposon mediated differential hybridisation |
| 02/01/2001 | CA2379834A1 Enzyme catalyzed anti-infective therapeutic agents |
| 02/01/2001 | CA2379818A1 Catalytic anti-factor viii allo-antibodies |
| 02/01/2001 | CA2379801A1 Receptors and associated proteins |
| 02/01/2001 | CA2379784A1 Cell cycle and proliferation proteins |
| 02/01/2001 | CA2379398A1 Nociceptin receptor orl-1 agonists for use in treating cough |
| 02/01/2001 | CA2378845A1 Vgf selective binding agents and methods of treating vgf-related disorders |
| 02/01/2001 | CA2378650A1 Process for the improvement of spermatozoa fertilization activity |
| 02/01/2001 | CA2378473A1 Modulation of platelet activation |
| 02/01/2001 | CA2378462A1 Ppar delta inhibitors for the treatment of cardiovascular diseases |
| 02/01/2001 | CA2378403A1 Novel polynucleotides and method for the use thereof |
| 02/01/2001 | CA2378371A1 Use of etodolac to treat cancer |
| 02/01/2001 | CA2378328A1 Method of promoting bone growth with hyaluronic acid and growth factors |
| 02/01/2001 | CA2375571A1 Human nervous system-associated proteins |
| 01/31/2001 | EP1072687A2 Method for testing metastatic potential and method for screening compounds with metastasis-suppressing activity |
| 01/31/2001 | EP1072680A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/31/2001 | EP1072607A2 Purine L-nucleosides, analogs and uses therof |
| 01/31/2001 | EP1071959A2 Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway |
| 01/31/2001 | EP1071956A1 Assays for autoantibodies |
| 01/31/2001 | EP1071955A1 Improved immunodiagnostic assays using reducing agents |
| 01/31/2001 | EP1071822A2 Fetal testing for prediction of low birth weight |
| 01/31/2001 | EP1071805A2 Adenoviral vectors for treating disease |
| 01/31/2001 | EP1071781A1 B-cell growth factor related protein |
| 01/31/2001 | EP1071772A2 Fizz proteins |
| 01/31/2001 | EP1071770A2 Glaucoma therapeutics and diagnostics based on a novel human transcription factor |
| 01/31/2001 | EP1071751A1 TRANSGENIC MAMMALS EXPRESSING MUTANT GP IIIa |
| 01/31/2001 | EP1071709A2 Dermatophagoides nucleic acid molecules, proteins and uses thereof |
| 01/31/2001 | EP1071698A1 Nucleic acid sequences and proteins associated with aging |
| 01/31/2001 | EP1071697A1 Regulated target expression for screening |
| 01/31/2001 | EP1071694A1 Staphylococcus aureus spo0j2: polynucleotide and protein |
| 01/31/2001 | EP1071667A1 Receptor ligands |
| 01/31/2001 | EP1071469A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071463A1 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071462A1 Methods and compositions using norastemizole in combination with leukotriene inhibitors |
| 01/31/2001 | EP1071461A1 Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition |
| 01/31/2001 | EP1071460A1 INTERNALIZING ErbB2 ANTIBODIES |
| 01/31/2001 | EP1071459A1 Methods to provoke anti-cancer immune responses |